BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2016

View Archived Issues

Shionogi recaps events of second quarter of fiscal 2016

Read More

Daiichi Sankyo reflects on achievements of second quarter of fiscal 2016

Read More

Eisai reviews pipeline highlights of second quarter of fiscal 2016

Read More

Sanofi offers overview of active third quarter 2016

Read More

Givinostat significantly counteracts histological disease progression in boys with DMD

Read More

Promising phase I/II results for PR1 peptide vaccine in patients with myeloid malignancies

Read More

Ruijin Hospital, Brandeis University and Xiamen University patent protein kinase inhibitors

Read More

Jiangsu Hengrui Medicine discloses IDO1 and/or TDO inhibitors

Read More

FDA awards orphan drug designation to Amryt's AP-102

Read More

FDA advisory committee votes on solithromycin submission for CABP

Read More

FDA approves Enbrel to treat children with moderate to severe plaque psoriasis

Read More

Genentech and Roche describe NMDA receptor modulators

Read More

Zucara Therapeutics receives investment from Canadian partners

Read More

University of British Columbia develops ERalpha antagonists

Read More

Researchers report new T2D risk loci in Jordan subpopulations

Read More

Cancer Research UK signs agreement with TYG Oncology

Read More

Pulmocide's PC-945 shows efficacy in mice

Read More

Apogenix achieves additional milestones under CANbridge Life Sciences deal

Read More

AdAlta and XL-protein collaborate to develop long-acting form of AD-114

Read More

Onxeo reports increased potency for Livatag compared with free doxorubicin

Read More

FDA grants orphan drug designation to veliparib

Read More

DCC mutations are associated with isolated ACC

Read More

MERIT study of macitentan in CTEPH meets primary endpoint

Read More

Aimmune Therapeutics wins equity investment from Nestle Health Science

Read More

Bayer seeks approvals for regorafenib in second-line HCC in U.S., E.U. and Japan

Read More

FDA clears IND for phase II trial of elafibranor in PBC

Read More

Bevacizumab-800CW tracer safe and tumor specific in cancer patients

Read More

Sandoz files application for approval of GP-2013 in Japan

Read More

EMA accepts MAA from Celltrion for CT-P6

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing